Bromocriptine reduces steatosis in obese rodent models
LM Davis, Z Pei, MA Trush, LJ Cheskin… - Journal of …, 2006 - Elsevier
BACKGROUND/AIMS: Obesity is a risk factor for glucose intolerance, steatosis, and
oxidative stress, characteristics of nonalcoholic fatty liver disease. Bromocriptine may have …
oxidative stress, characteristics of nonalcoholic fatty liver disease. Bromocriptine may have …
[引用][C] Bromocriptine reduces steatosis in obese rodent models
LM DAVIS, Z PEI, MA TRUSH… - Journal of …, 2006 - pascal-francis.inist.fr
Bromocriptine reduces steatosis in obese rodent models CNRS Inist Pascal-Francis CNRS
Pascal and Francis Bibliographic Databases Simple search Advanced search Search by …
Pascal and Francis Bibliographic Databases Simple search Advanced search Search by …
Bromocriptine reduces steatosis in obese rodent models.
LM Davis, Z Pei, MA Trush, LJ Cheskin… - Journal of …, 2006 - europepmc.org
Methods We performed a randomized, controlled experiment in genetically obese fatty
Zucker rats and diet-induced obese rats to assess for behavioral and peripheral anti-obesity …
Zucker rats and diet-induced obese rats to assess for behavioral and peripheral anti-obesity …
[PDF][PDF] Bromocriptine reduces steatosis in obese rodent modelsq
LM Davis, Z Pei, MA Trush, LJ Cheskin… - Journal of …, 2006 - academia.edu
Background/Aims: Obesity is a risk factor for glucose intolerance, steatosis, and oxidative
stress, characteristics of nonalcoholic fatty liver disease. Bromocriptine may have anti …
stress, characteristics of nonalcoholic fatty liver disease. Bromocriptine may have anti …
Bromocriptine reduces steatosis in obese rodent models
LM Davis, Z Pei, MA Trush, LJ Cheskin… - Journal of …, 2006 - pubmed.ncbi.nlm.nih.gov
Background/aims Obesity is a risk factor for glucose intolerance, steatosis, and oxidative
stress, characteristics of nonalcoholic fatty liver disease. Bromocriptine may have anti …
stress, characteristics of nonalcoholic fatty liver disease. Bromocriptine may have anti …
Bromocriptine reduces steatosis in obese rodent models
LM Davis, Z Pei, MA Trush, LJ Cheskin… - Journal of …, 2006 - infona.pl
Obesity is a risk factor for glucose intolerance, steatosis, and oxidative stress, characteristics
of nonalcoholic fatty liver disease. Bromocriptine may have anti-obesity, insulin-sensitizing …
of nonalcoholic fatty liver disease. Bromocriptine may have anti-obesity, insulin-sensitizing …
Bromocriptine reduces steatosis in obese rodent models
LM Davis, Z Pei, MA Trush, LJ Cheskin… - Journal of …, 2006 - pure.johnshopkins.edu
Background/Aims: Obesity is a risk factor for glucose intolerance, steatosis, and oxidative
stress, characteristics of nonalcoholic fatty liver disease. Bromocriptine may have anti …
stress, characteristics of nonalcoholic fatty liver disease. Bromocriptine may have anti …
Bromocriptine reduces steatosis in obese rodent models
LM Davis, Z Pei, MA Trush, LJ Cheskin… - Journal of …, 2006 - journal-of-hepatology.eu
Background/Aims Obesity is a risk factor for glucose intolerance, steatosis, and oxidative
stress, characteristics of nonalcoholic fatty liver disease. Bromocriptine may have anti …
stress, characteristics of nonalcoholic fatty liver disease. Bromocriptine may have anti …
Bromocriptine reduces steatosis in obese rodent models
LM Davis, Z Pei, MA Trush, LJ Cheskin… - Journal of …, 2006 - hero.epa.gov
BACKGROUND/AIMS: Obesity is a risk factor for glucose intolerance, steatosis, and
oxidative stress, characteristics of nonalcoholic fatty liver disease. Bromocriptine may have …
oxidative stress, characteristics of nonalcoholic fatty liver disease. Bromocriptine may have …
Paper alert
European Journal of Gastroenterology & Hepatology, 2006 - journals.lww.com
Background/aims: Obesity is a risk factor for glucose intolerance, steatosis, and oxidative
stress, characteristics of nonalcoholic fatty liver disease. Bromocriptine may have anti …
stress, characteristics of nonalcoholic fatty liver disease. Bromocriptine may have anti …